In the CheckMate 238 trial, patients with resected stage IIIB–C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results